Skip to main content
Science / Explained
Myths, Read Against the EvidenceArticle 15 of 27

Do GLP-1 peptides cause gallbladder problems?

Yes. And so does fast weight loss itself. This is a real safety topic.

THE NUMBERS

The Wegovy label includes acute gallbladder disease as a warning. The cardiovascular trial of semaglutide (SELECT) put numbers on it: gallbladder events showed up in about 1 in 36 people on the peptide versus about 1 in 43 on placebo. A small but real increase.

THE MECHANISM

The mechanism is biliary chemistry: when body fat drops fast, cholesterol concentration in bile goes up, and slower gut motility lets gallstones form.

The same risk exists with bariatric surgery, very-low-calorie diets, and other rapid-weight-loss methods. The peptide contributes to the conditions; the speed of weight loss is the dominant lever.

What this means

The safety topic is real and well-mapped. The peptide contributes, but the pace of weight loss is what most determines the risk.

The peptide isn't the cause. The speed of the weight loss is.

← Previous
Do GLP-1 peptides damage the liver?
Next →
Do GLP-1 peptides cause pancreatitis?
References01 sources
  1. See source line · 2026
    Wegovy prescribing information (FDA-approved label), Acute Gallbladder Disease warning. SELECT trial: Lincoff et al. 2023, *New England Journal of Medicine* (PMID 37952131, DOI 10.1056/NEJMoa2307563).
    Source line — see article body
Do GLP-1 peptides cause gallbladder problems? · Catalyst / Science Explained · Catalyst